Watching Cassava Sciences; Shares See Volume To The Upside As Traders Circulate Unconfirmed Analyst Comments Suggesting "Confirmed Guidance For Completion Of Its First Pivotal Alzheimer's Trial By Year-End 2024; Anticipating A Potential Settlement Of An SEC Investigation" Reiterating Their Buy Rating And $107 PT
Portfolio Pulse from Benzinga Newsdesk
Cassava Sciences (SAVA) shares see increased volume as traders circulate unconfirmed analyst comments suggesting confirmed guidance for the completion of its first pivotal Alzheimer's trial by the end of 2024 and a potential settlement of an SEC investigation. Analysts reiterate their buy rating and $107 price target.

August 08, 2024 | 6:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cassava Sciences (SAVA) shares see increased volume due to unconfirmed analyst comments suggesting the completion of its first pivotal Alzheimer's trial by the end of 2024 and a potential settlement of an SEC investigation. Analysts reiterate their buy rating and $107 price target.
The unconfirmed analyst comments suggest significant positive developments for Cassava Sciences, including the completion of a pivotal Alzheimer's trial and a potential settlement of an SEC investigation. These factors, along with the reiterated buy rating and $107 price target, are likely to drive short-term positive sentiment and price movement.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100